[Employment Status Gynecological Cancer Patients Received Paclitaxel plus Carboplatin(TC)Therapy]

We investigated the employment status of patients who received tri‒weekly TC therapy as primary treatment for initial ovarian cancer and uterine cancer at the time of starting treatment and were receiving wages from work. Six patients continued working at the time chemotherapy started, and the carcinomas were ovarian cancer in 2 cases and uterine cancer in 4 cases. The 6 patients who continued working completed the planned course. There was no postponement of treatment due to side effects during the planned treatment period. Six out of 6 patients had Grade 2 peripheral neuropathy. The fact that there was no work that was hindered by peripheral neuropathy is thought to be the reason why chemotherapy could be continued without quitting or taking a leave of absence.